The Federal Trade Commission gave final approval to Novartis’ divesting of assets related to its BRAF- and MEK-inhibitor drugs to satisfy the agency’s concerns that the drugmaker’s $16 billion acquisition of...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: